Pharmaceutical News

RSS

Vitamin B counteracts levels of DDT in women who are more likely to get, stay pregnant

Women who have adequate levels of B vitamins in their bodies are more likely to get and stay pregnant even when they also have high levels of a common pesticide known to have detrimental reproductive effects, according to new Johns Hopkins Bloomberg School of Public Health research.

5 Jan 2015

Study confirms safety of two measles-containing vaccines

A 12-year study of two measles-containing vaccines, published today in Pediatrics, found that seven main adverse outcomes were unlikely after either vaccine.

5 Jan 2015

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia Pharmaceuticals, Inc. today announced that it has secured an additional $10 million from current investors to support development of the company's lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP).

5 Jan 2015

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.

5 Jan 2015

TxCell announces further enhancement to development of Ovasave for IBD treatment

Paulsen Foundation to provide specialist management and scientific and development expertise that is dedicated to advanced therapies, i.e. cellular and gene therapies. This new class of highly promising biological therapies includes TxCell’s Ovasave.

5 Jan 2015

Saatchi Bill: an interview with Dr. David Collingridge, Editor-in-Chief, The Lancet Oncology

The intention of the Medical Innovation Bill is to encourage and support doctors to explore new medicines for their patients when they believe existing options are no longer achieving good outcomes.

4 Jan 2015

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients.

31 Dec 2014

Sex enhancement product recalled after Health Canada test finds undeclared drug ingredient

One lot of the sex enhancement product "Forta for Men" (NPN 80045132) is being recalled after Health Canada testing confirmed it contains an undeclared drug: homosildenafil.

31 Dec 2014

Tikcro enters into research and license agreement with Yeda

Tikcro Technologies Ltd. today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel.

30 Dec 2014

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.

30 Dec 2014

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.

30 Dec 2014

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

29 Dec 2014

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.

25 Dec 2014

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Cancer could be broken down by its evolving defense mechanism

Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease.

24 Dec 2014

CorMedix signs Neutrolin sales/distribution agreement with Arabian Trade House

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, announced today the first signed Middle East sales/distribution agreement for lead product Neutrolin with distributor Arabian Trade House in the Kingdom of Saudi Arabia.

23 Dec 2014

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

EB Pharma, LLC., a subsidiary of Eiger BioPharmaceuticals, Inc., announced that it has executed an agreement with Janssen Pharmaceutica NV, for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound.

23 Dec 2014

Pharmaceutical News

Vitamin B counteracts levels of DDT in women who are more likely to get, stay pregnant

Study confirms safety of two measles-containing vaccines

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

TxCell announces further enhancement to development of Ovasave for IBD treatment

Saatchi Bill: an interview with Dr. David Collingridge, Editor-in-Chief, The Lancet Oncology

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

Sex enhancement product recalled after Health Canada test finds undeclared drug ingredient

Tikcro enters into research and license agreement with Yeda

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Newron, Zambon announce re-submission of safinamide NDA to FDA

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Cancer could be broken down by its evolving defense mechanism

CorMedix signs Neutrolin sales/distribution agreement with Arabian Trade House

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News